Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study

Robert B M Landewé,1 Denis Podubnyy,2,3 Proton Rahman,4 Filip E Van den Bosch,5,6 Rebecca Bolce,7 Soyi Liu Leage,7 Jeffrey R Lisse,7 So Young Park,7 Lianne Gensler8

ABSTRACT

Objectives To evaluate the recapture of response with open-label (OL) ixekizumab (IXE) retreatment at week 104 in patients with axial spondyloarthritis who flared after withdrawal of IXE therapy.

Methods COAST-Y (NCT03129100) is a phase III extension study that included a double-blind, placebo-controlled, randomised withdrawal-retreatment period (RWRP). Patients who achieved remission (Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3 (inactive disease, ID) at least once at week 16 or 20 and <2.1 (low disease activity, LDA) at both visits) were randomised 2:1 at week 24 to continue IXE or withdraw to placebo. Patients who subsequently flared were switched to OL IXE every 2 or 4 weeks (Q2W or Q4W) at the next visit. The proportions of patients who recaptured ASDAS LDA and ID were summarised for those who experienced flare.

Results Of the 155 patients who entered the RWRP (placebo, n=53; IXE Q4W, n=48; IXE Q2W, n=54), 138 (89%) completed week 104. Of the placebo-treated patients (n=53), 28 (53%) experienced a flare during weeks 24–104 of these, 4 (14%) recaptured ASDAS LDA before retreatment with OL IXE, and 23 (82%) recaptured ASDAS LDA and 19 (68%) met ASDAS ID after retreatment. Of the continuously treated IXE patients (n=102), 13 experienced flare; 7 of 13 (54%) recaptured ASDAS LDA before switching to OL IXE retreatment, while 5 of 13 (38%) recaptured ASDAS LDA and 4 of 13 (31%) met ID after switching.

Conclusions Ninety-six per cent of patients withdrawn to placebo recaptured at least ASDAS LDA and 71% recaptured ASDAS ID with IXE retreatment at week 104. This may provide support to patients who may require a brief interruption in therapy.

INTRODUCTION

Patients with axial spondyloarthritis (axSpA) experience a high burden of disease and rely on long-term therapy for maintenance of disease control.1,2 The European Alliance of Associations for Rheumatology guidelines and current treat-to-target recommendations suggest that once a patient achieves a state of remission or low disease activity (LDA), physicians may taper, but not stop, treatment.3 However, patients frequently must pause active treatment due to elective surgery or in the event of an infection. During a follow-up period ranging from 36 to 52 weeks (with a median of 52 weeks), between 76% and 100% of patients with axSpA experience a flare after stopping or discontinuing an anti-tumour necrosis factor inhibitor (TNFi) without tapering.4 Thus, it is of importance for both physicians and patients to know that recapture of treatment response is possible after a pause, unexpected or otherwise, in therapy.

COAST-Y is the first study to evaluate the effect of continuing versus withdrawing an interleukin (IL)-17A antagonist, ixekizumab (IXE), on the maintenance of disease control in patients with radiographic (r) and non-radiographic (nr) axSpA through 104 weeks.5 The aim of the present analysis is to evaluate the recapture of response with...
open-label (OL) IXE retreatment at week 104 in patients with axSpA who flared after withdrawal of IXE therapy.

**Methods**

**Patients**

COAST-Y (NCT03129100) enrolled patients (n=773) from any of the three originating studies: two on r-axSpA (COAST-V, NCT02696785; COAST-W, NCT02696798) and one on nr-axSpA (COAST-X, NCT02757352). Complete eligibility criteria for the three originating studies and COAST-Y have been published.5–8

**Study design**

COAST-Y is a long-term extension study that contained an OL lead-in period and a double-blind, placebo-controlled, randomised withdrawal-retreatment period (RWRP) (online supplemental figure 1).5 Patients entered a 24-week lead-in period (weeks 0–24) and continued either 80 mg IXE every 2 weeks (Q2W) or every 4 weeks (Q4W). Patients who continuously received blinded placebo up to the completion of COAST-X were assigned to IXE Q4W during the lead-in period of COAST-Y. Patients from COAST-V and COAST-W continued on the same treatment they were receiving at the end of the originating trial.

On completion of the lead-in period at week 24, patients who achieved remission (n=155) (defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) of <1.3 at least once at week 16 or week 20 and <2.1 at both visits) entered the RWRP. Patients were randomly assigned in equal proportions to continue blinded IXE Q4W, continue blinded IXE Q2W or withdraw to placebo. Thus, the observed withdrawal period occurred after the 24-week lead-in, for 80 weeks between week 24 and week 104.

Patients who experienced a flare (defined as an ASDAS of ≥2.1 at two consecutive visits or an ASDAS of >3.5 at any visit) during the RWRP between weeks 24 and 104 were retreated in an OL manner at the next visit with the same dose of IXE dosing regimen received during the lead-in period.

**Outcomes**

The primary outcome of COAST-Y was the proportion of patients in the randomised withdrawal population who did not experience a flare during the RWRP; the results have previously been published.5 This analysis describes the recapture rates at week 104 of patients who were rerandomised to either placebo (IXE withdrawal) or IXE who experienced a flare. A recapture of treatment response refers to a patient achieving either ASDAS LDA or ASDAS inactive disease (ID) following retreatment with IXE therapy during the RWRP. Other outcomes of COAST-Y at week 104 included the proportion of flare-free patients in the combined IXE Q2W and IXE Q4W group, and IXE Q2W group versus those withdrawn to placebo group.

**Statistical analysis**

The proportions of patients who experienced a flare and recaptured ASDAS LDA and ASDAS ID before or after IXE retreatment are reported using descriptive statistics. A post-hoc assessment was conducted to evaluate the ASDAS disease activity category at the individual patient-level from weeks 24 to 64. The Kaplan-Meier product limit method was used to estimate the time to flare. Individual patient-level data on the ASDAS disease activity response status during the COAST-Y study (weeks 0–104) are visually presented for patients who entered the RWRP

**Table 1** Recapture of treatment response before or after switching to OL IXE through 104 weeks among patients randomised to placebo (IXE withdrawal) who experienced a flare and were retreated

<table>
<thead>
<tr>
<th>Total patients who flared and were switched to OL IXE retreatment</th>
<th>Placebo (IXE withdrawal) (N=28)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASDAS disease activity status</td>
<td>LDA ID</td>
</tr>
<tr>
<td>Recaptured response before OL IXE retreatment, n</td>
<td>4 1</td>
</tr>
<tr>
<td>Recaptured response with OL IXE retreatment (&gt;16 weeks), n</td>
<td>23 14</td>
</tr>
<tr>
<td>Recaptured response with OL IXE retreatment (&gt;16 weeks), n</td>
<td>0 5</td>
</tr>
<tr>
<td>Total patients who recaptured response by week 104, n (%)</td>
<td>27/28 (96) 20/28 (71)</td>
</tr>
</tbody>
</table>

In each column, the denominator is 28. A total of 4 patients met the criteria for flare and were not retreated. 20 patients had achieved ASDAS ID, while 8 patients achieved ASDAS LDA before flare and OL IXE retreatment.

ASDAS, Ankylosing Spondylitis Disease Activity Score; ID, inactive disease; IXE, ixekizumab; LDA, low disease activity including ID; N, number of patients in the analysis population; OL, open-label.

**Table 2** Recapture of first treatment response before or after switching to OL IXE through 104 weeks among patients continuously treated with IXE who experienced a flare and were switched to OL IXE

<table>
<thead>
<tr>
<th>Total patients who flared and were switched to OL IXE retreatment</th>
<th>Continuous IXE (N=13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASDAS disease activity status</td>
<td>LDA ID</td>
</tr>
<tr>
<td>Recaptured response before OL IXE retreatment, n</td>
<td>7 1</td>
</tr>
<tr>
<td>Recaptured response with OL IXE retreatment (&gt;16 weeks), n</td>
<td>2 3</td>
</tr>
<tr>
<td>Recaptured response with OL IXE retreatment (&gt;16 weeks), n</td>
<td>3 1</td>
</tr>
<tr>
<td>Total patients who recaptured response by week 104, n (%)</td>
<td>12/13 (92) 5/13 (38)</td>
</tr>
</tbody>
</table>

In each column, the denominator is 13. Only one patient met the criteria for flare and was not retreated. Six patients had achieved ASDAS ID and seven patients achieved ASDAS LDA before flare and OL IXE retreatment.

ASDAS, Ankylosing Spondylitis Disease Activity Score; ID, inactive disease; IXE, ixekizumab; LDA, low disease activity including ID; N, number of patients in the analysis population; OL, open-label.
(n=155). Post-hoc assessments were also conducted to evaluate potential predictors of flare. Due to a small number of patients experiencing flares with continuous IXE treatment, the two IXE treatment groups (IXE Q4W and IXE Q2W) were pooled into a combined IXE group. Post-hoc analyses were conducted to evaluate potential predictors of flare. Variables with p values <0.2 were entered into the multivariate logistic model for step-wise selection, with a p value of 0.1 a criterion for removal and stay. Interaction of each of the variables of interest with IXE treatment withdrawal was also evaluated in an individual logistic regression model. Variables and their corresponding interaction were entered into the multivariate logistic regression model for variables found in the stepwise selection procedure; a backward selection was used to build the final model.

Patient and public involvement
Patients were not involved in the design or conduct of the study, development of outcomes, or dissemination of study results.

RESULTS
Patients
Of the 773 patients enrolled in COAST-Y, 741 completed the 24-week lead-in period and 155 patients met the criteria for remission and entered the RWRP. Of these, 138 patients completed week 104. Baseline demographics and disease characteristics of patients who entered the RWRP (n=155) were balanced across treatment arms (online supplemental table 1).

Incidence rates of flare through 104 weeks
At week 104, significantly more patients in the combined IXE group (75.5%, p<0.001; IXE Q4W: 75.0%, p<0.001; IXE Q2W: 75.9%, p<0.001) remained flare-free versus placebo (figure 1). Notably, 35.8% of patients receiving placebo never experienced flare.

At week 104, the Kaplan-Meier estimate of median time to first flare was 52.1 weeks for placebo (IXE withdrawal). Continuing IXE treatment significantly delayed time to flare versus withdrawal to placebo for the combined IXE, IXE Q4W and IXE Q2W groups (p<0.001 for all; figure 2).

When the incidence of a flare was assessed using ASDAS worsening of ≥0.9 points, at week 104, significantly more patients in the combined IXE group (68.2%, p<0.001; IXE Q4W: 73.2%, p<0.001; IXE Q2W: 63.8%, p<0.001) remained flare-free versus placebo (20.8%; online supplemental figure 2). A total of 22% of patients receiving placebo never experienced a flare.

Recapture of treatment response before or after IXE retreatment
Of the placebo (IXE withdrawal)-treated patients (n=53), a total of 28 patients experienced a flare and were retreated with OL IXE (table 1). Around 96% (27 of 28) of these patients recaptured ASDAS LDA by week 104; 4 patients recaptured ASDAS LDA before retreatment and 23 patients recaptured that response within 16 weeks of retreatment.

Of the placebo-treated patients who experienced a flare, 71% (20 of 28) recaptured ASDAS ID by week 104; 1 patient recaptured response before retreatment, 14 patients recaptured ASDAS ID within 16 weeks of OL IXE, while 5 patients recaptured an ASDAS ID response after 16 weeks of OL IXE retreatment.

Of the patients who were continuously treated with IXE (IXE Q4W, n=48; IXE Q2W, n=54), a total of 13 patients experienced a flare and were retreated with OL IXE (IXE Q4W, n=7; IXE Q2W, n=6, table 2). Around 92% (12 of 13) of patients recaptured ASDAS LDA by week 104 (IXE Q4W, n=7; IXE Q2W, n=5); seven patients recaptured ASDAS LDA before OL IXE retreatment, two patients recaptured within 16 weeks,
Spondyloarthritis

while three patients recaptured an ASDAS LDA response after 16 weeks of OL IXE retreatment.

A total of 5 (IXE Q4W, n=3; IXE Q2W, n=2) out of 13 (IXE Q4W, n=7; IXE Q2W, n=6) patients continuously treated with IXE, who experienced a flare and were retreated, recaptured an ASDAS ID response by week 104; one patient recaptured ASDAS ID before OL IXE retreatment, three patients recaptured within 16 weeks of retreatment, while one patient recaptured ASDAS ID after 16 weeks of OL IXE retreatment.

Sustainability of treatment response

Heatmaps were generated to show the maintenance of ASDAS status through 104 weeks among patients who were randomised to placebo, IXE Q4W or IXE Q2W at week 24 (figure 3). Individual patient ASDAS disease activity, as ASDAS ID (ASDAS <1.3) (green), ASDAS LDA (ASDAS ≥1.3 and <2.1) (yellow), ASDAS high disease activity (ASDAS ≥2.1 and <3.5) (orange) and ASDAS very high disease activity (ASDAS ≥3.5) (red), is shown for patients who did and did not experience a flare in disease activity, at 4-weekly intervals from weeks 24-64 and weeks 100–104 of COASTY and at 12-weekly intervals from weeks 64 to 100. Each row corresponds to one patient, with patients organised in order of descending disease activity. In addition, patients who experienced a flare in disease activity and were retreated with OL IXE (figure 3A) or were switched to OL IXE (figure 3B,C) are presented at the top of the heatmap. The heatmap diagrams illustrate that the majority of patients who achieve ASDAS LDA or lower at week 24 sustain that treatment response through 104 weeks of COASTY.

Predictors of flare

Post-hoc analysis for the randomised withdrawal-retreatment intention-to-treat population was conducted to identify patient characteristics that were associated with flare (online supplemental tables 2–4). Multivariate model analysis identified the ASDAS area under the curve between weeks 0 and 24 of COASTY as being associated with flare (OR 1.08, 95% CI 1.03 to 1.14; online supplemental table 3).

In addition, when the interaction of treatment by the potential predictors of flare was assessed, treatment (IXE withdrawal) and ASDAS area under the curve were identified as predictors of flare (online supplemental table 4). A significant interaction of IXE withdrawal by symptom duration at the beginning of COASTY was also observed, indicating longer symptom duration (≥5 years) was associated with flare in patients who were withdrawn to placebo, whereas this association was not observed in patients who continued IXE treatment.

DISCUSSION

COASTY is the first study to compare the maintenance of disease control in patients with axSpA who continued versus those who withdrew an IL-17A antagonist (IXE) after having achieved remission. This analysis demonstrates that the majority of patients who were withdrawn from IXE to placebo and experienced a flare recaptured either ASDAS LDA or ID within 16 weeks of OL IXE retreatment.

Over half of the patients who were withdrawn to placebo and experienced a flare recaptured ASDAS ID before or within 16 weeks of retreatment. Almost all (96%) placebo-treated patients who experienced a flare recaptured ASDAS LDA by week 104, with 4 out of 28 patients regaining ASDAS LDA before any retreatment at all. While the population of patients who flared in patients randomised to blinded IXE was smaller (n=13), one has to wonder if the nocebo effect was in play once they went on blinded IXE, as 92% did recapture ASDAS LDA once they were on OL IXE and 38% recaptured ASDAS LDA by week 104.

Some studies assessing the maintenance of ASDAS ID or remission following withdrawal of active treatment also assessed predictors of remission or ID. In ABILITY-3, younger age (continuous variable), male sex and positive human leukocyte antigen B27 (HLA-B27) were found to be predictors of ASDAS ID.3 In RE-EMBARK, male sex and age <40 years were significant predictors of regaining ID following a flare and subsequent 12-week retreatment with etanercept.16 In contrast, although the present analysis did not assess predictors of ASDAS ID, we report that ASDAS area under the curve was one of the characteristics associated with flare, meaning that patients with higher disease activity over time were more likely to experience a flare than those with consistently low disease activity. A 2016 systematic review noted that the time under remission before tapering of TNFi was associated with a better outcome; however, no clear predictors have yet been identified.8 This may be somewhat attributable to the lack of a clear consensus regarding the definition of a flare in patients with axSpA.

Possible limitations of this analysis include the fact that different studies use different definitions of flare and remission, which limits direct comparisons among analyses.11 The ASDAS definition of flare was not used in the present study and it is worth noting that some patients who were ASDAS=2.0 and moved to ASDAS=2.1 at two consecutive visits did not experience a flare according to the ASDAS definition. It is also important to note that the method of active treatment discontinuation in the present study is not in line with what is recommended for clinical practice (tapering of treatment).

The present analysis demonstrated that patients continuously treated with IXE were less likely to experience flare compared with patients receiving placebo (IXE withdrawal). The vast majority of patients withdrawn from IXE to placebo recaptured at least LDA and over half of those patients met the criteria for ID with IXE retreatment. These data may provide support to patients who require interruption in active therapy.

Author affiliations

1 Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands
2 Rheumatology Department, Charité – Universitätsmedizin Berlin, Berlin, Germany
3 German Rheumatism Research Centre, Berlin, Germany
4 Division of Rheumatology, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada
5 Department of Internal Medicine and Pediatrics, Ghent University, Gent, Belgium
6 VIB Center for Inflammation Research, Ghent, Belgium
7 Eli Lilly and Company, Indianapolis, Indiana, USA
8 Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA

Acknowledgements The authors thank Ann Leung MS of Synexus Health and Stephanie Strakbein MS of Eli Lilly and Company for statistical support, and Edel Hughes PhD of Eli Lilly and Company for writing and editorial support.

Contributors Eli Lilly contributed to the study design, data collection, data analysis, data interpretation, preparation of the manuscript and the decision to submit the paper for publication. FEVdB contributed to study design. DP contributed


Downloaded from http://ard.bmj.com/ on 13 September 2022 by guest. Protected by copyright.
to acquisition of data. SLP and SYP contributed to analysis of data. All authors contributed to the interpretation of data. All authors had full access to all the data in the study, reviewed the drafts and approved the final version of the manuscript. RBML is guarantor of the work.

Funding
This work was supported by Eli Lilly and Company (Indianapolis, Indiana, USA).

Competing interests
RBML reports grants or contracts from AbbVie, Galapagos, Pfizer and UCB; personal fees from AbbVie, Celgene, Eli Lilly and Company, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB; consulting fees from Rheumatology Consultancy; and is a EULAR council member. DP reports grants or contracts from AbbVie, Eli Lilly and Company, MSD, Novartis and Pfizer; personal fees from AbbVie, Bocla, Eli Lilly and Company, Gilead, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Samsung Biopics and UCB; and speaking fees and/or honoraria from AbbVie, Bristol Myers Squibb, Eli Lilly and Company, MSD, Novartis, Pfizer and UCB. PR reports research grants from Janssen and Novartis; speaking fees and/or honoraria from Abbott, AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis and Pfizer; travel support from Janssen; and participated on an advisory board for Abbott, AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis and Pfizer. FEVdB reports grant support from Merck and consulting fees from AbbVie, Amgen and Eli Lilly and Company, RB, SLL, JRL and SYP are employees of Eli Lilly and Company and own stock or stock options. LG reports consulting fees from AbbVie, Amgen and Eli Lilly and Company. RBML is guarantor of the work.

Patient and public involvement
Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication
Not required.

Ethics approval
This study involves human participants. COAST-Y was approved by the main ethics committee Schulum Associates IRB, Cincinnati, Ohio, USA (IRB # 201607390) and the study was approved by the ethical review boards at each of 127 total participating sites. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available upon reasonable request. Lilly provides access to all individual participant data collected during the trial, after anonymisation, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication study has been approved in the USA and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivi.org.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Robert B M Landewé http://orcid.org/0000-0002-0577-6620
Denis Poddbubny http://orcid.org/0000-0002-4537-6015
Filip E Van den Bosch http://orcid.org/0000-0002-3561-5932

REFERENCES